• Aliases: BMS-936558, MDX1106, ONO-4538
    • Fully human IgG4 monoclonal antibody targeting PD-1 receptor on activated T cells
    • FDA approved for recurrent or metastatic SCCHN, classic Hodgkin lymphoma progressing after stem cell transplant and brentuximab vedotin, unresectable or metastatic melanoma, metastatic NSCLC (nonsquamous), advanced renal cell carcinoma, and locally advanced or metastatic urothelial carcinoma
    • Recommended dose: 3 mg/kg IV every 2 weeks (head and neck, Hodgkin, SCLC); 240 mg IV every 2 weeks (melanoma, NSCLC, renal cell, urothelial); combination with ipilimumab, start dose at 1 mg/kg and then increase it to 3 mg/kg
    Other topics in Targeted and Immunotherapy Agents